Article Data

  • Views 473
  • Dowloads 151

Original Research

Open Access

FOXD2-AS1 inhibits the proliferation and migration in prostate cancer: an in vitro and in vivo study

  • Xiong Mei1
  • Yongli Nie1
  • Jun Chen2
  • Wei Wang3,*,

1Department of Oncology, Sinopharm Han Jiang Hospital, 442700 Shiyan, Hubei, China

2Experimental center, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, 442008 Shiyan, Hubei, China

3Department of Medical Laboratory, Chongqing University Cancer Hospital, Chongqing Cancer Institute, Chongqing Cancer Hospital, 400010 Chongqing, China

DOI: 10.22514/jomh.2023.092 Vol.19,Issue 9,September 2023 pp.119-126

Submitted: 06 July 2023 Accepted: 28 August 2023

Published: 30 September 2023

*Corresponding Author(s): Wei Wang E-mail:


FOXD2 Adjacent Opposite Strand RNA 1 (FOXD2-AS1), a long noncoding RNA (lncRNA), exhibits specifically elevated in numerous cancerous cells. Numerous studies have shown that FOXD2-AS1 encourages cellular proliferation, migration and invasion. Nevertheless, the exact mechanism through which FOXD2-AS1 contributes to prostate cancer (PCa) remains unclear. Consequently, we aimed to explore the implications of FOXD2-AS1 on the growth of PCa. Initially, an elevation of FOXD2-AS1 observed in PCa cells (PC-3, DU145 and Lncap) than the prostate normal cell line RWPE2. Then, PC-3 cells were tranafected with shFOXD2-AS1, sh-Numerical Control (shNC) or FOXD2-AS1 to assess the implications of FOXD2-AS. Cell growth was measured with cell counting kit-8 (CCK8) and 5-ethynyl-2′-deoxyuridine (EDU) assays, and cell invasion and migration were assessed by Transwell assays, which demonstrated that FOXD2-AS1 silence impeded proliferation, migration and invasion of PC-3 cells. Additionally, we discovered that FOXD2-AS1 bonded with miR-206/programmed cell death protein 10 (PDCD10) trough analyzing the interaction sites of lncRNA, miRNA and protein. Then, these interaction abilities were confirmed by dual-luciferase reporter assays and RT-qPCR, suggesting FOXD2-AS1 could upregulate the amount of PDCD10 through suppressing miR-206. Furthermore, the role of FOXD2-AS1 silencing on PCa carcinogenesis were assessed. In vivo experiment, shFOXD2-AS1 led to a notable reduction in both the size and weight of PCa. These findings indicated that FOXD2-AS1 silencing effectively hindered the progression of prostate cancer. In conclusion, the upregulation of FOXD2-AS1 was observed in PCa, and the knockdown of FOXD2-AS1 could alleviated tumor development by targeting miR-206 to upregulate PDCD10 expression.


FOXD2-AS1; Prostate cancer; miR-206; PDCD10

Cite and Share

Xiong Mei,Yongli Nie,Jun Chen,Wei Wang. FOXD2-AS1 inhibits the proliferation and migration in prostate cancer: an in vitro and in vivo study. Journal of Men's Health. 2023. 19(9);119-126.


[1] Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes & Development. 2018; 32: 1105–1140.

[2] Monika Kuzma, Mária Breznická, Ján Kliment. Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents. Journal of Men’s Health. 2023; 19: 1–7.

[3] Murillo-Garzón V, Kypta R. WNT signalling in prostate cancer. Nature Reviews Urology. 2017; 14: 683–696.

[4] Li W, Xu W, Sun K, Wang F, Wong TW, Kong A. Identification of novel biomarkers in prostate cancer diagnosis and prognosis. Journal of Biochemical and Molecular Toxicology. 2022; 36: e23137.

[5] Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Molecular Cell. 2022; 82: 2252–2266.

[6] Li R, Wang X, Zhu C, Wang K. LncRNA PVT1: a novel oncogene in multiple cancers. Cellular & Molecular Biology Letters. 2022; 27: 84.

[7] Zhao W, Zhu X, Jin Q, Lin B, Ji R. The lncRNA NEAT1/miRNA-766-5p/E2F3 regulatory axis promotes prostate cancer progression. Journal of Oncology. 2022; 2022: 1866972.

[8] Ferri C, Di Biase A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. Journal of Experimental & Clinical Cancer Research. 2022; 41: 20.

[9] Zhang Y, Guo S, Wang S, Li X, Hou D, Li H, et al. LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7a11 signaling. Ecotoxicology and Environmental Safety. 2021; 220: 112376.

[10] Guo F, Guo R, Zhang L. Downregulation of lncRNA FOXD2-AS1 confers radiosensitivity to gastric cancer cells via miR-1913/SETD1A axis. Cytogenetic and Genome Research. 2022; 162: 10–27.

[11] Liang Y, Wang H, Song R, Yin X. LncRNA FOXD2-AS1 promotes the retinoblastoma cell viability and migration by sponging miR-31. BioMed Research International. 2022; 2022: 7723425.

[12] Zhang Y, Hu J, Zhou W, Gao H. LncRNA FOXD2-AS1 accelerates the papillary thyroid cancer progression through regulating the miR-485-5p/KLK7 axis. Journal of Cellular Biochemistry. 2019; 120: 7952–7961.

[13] Hu W, Feng H, Xu X, Huang X, Huang X, Chen W, et al. Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis. Cancer Medicine. 2020; 9: 5620–5631.

[14] Dong C, Fan B, Ren Z, Liu B, Wang Y. CircSMARCA5 facilitates the progression of prostate cancer through miR-432/PDCD10 axis. Cancer Biotherapy and Radiopharmaceuticals. 2021; 36: 70–83.

[15] Fu X, Zhang W, Su Y, Lu L, Wang D, Wang H. MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer. The Prostate. 2016; 76: 543–551.

[16] Xu K, Fei W, Huo Z, Wang S, Li Y, Yang G, et al. PDCD10 promotes proliferation, migration, and invasion of osteosarcoma by inhibiting apoptosis and activating EMT pathway. Cancer Medicine. 2023; 12: 1673–1684.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (

Submission Turnaround Time